New hope to stop aggressive breast Cancer's return
NCT ID NCT07486687
Summary
This large, late-stage trial aims to see if adding the drug pembrolizumab to standard follow-up treatment helps prevent cancer from coming back in people with early triple-negative breast cancer. It will enroll 1,000 patients whose cancer did not completely disappear after initial chemotherapy and pembrolizumab treatment. The study will compare outcomes for those who receive the extra drug versus those who receive standard care alone, focusing on survival and quality of life.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER STAGE II are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.